TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Director Acquires $49,990.50 in Stock

TFF Pharmaceuticals, Inc. (NASDAQ:TFFPGet Rating) Director Aaron G.L. Fletcher purchased 43,470 shares of TFF Pharmaceuticals stock in a transaction dated Tuesday, November 22nd. The shares were purchased at an average cost of $1.15 per share, for a total transaction of $49,990.50. Following the completion of the transaction, the director now owns 143,470 shares of the company’s stock, valued at $164,990.50. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

TFF Pharmaceuticals Price Performance

Shares of TFFP traded down $0.09 during trading hours on Thursday, reaching $1.35. The stock had a trading volume of 183,287 shares, compared to its average volume of 450,734. TFF Pharmaceuticals, Inc. has a 52 week low of $1.06 and a 52 week high of $9.96. The firm has a 50-day moving average of $3.14 and a 200 day moving average of $4.66.

Institutional Investors Weigh In On TFF Pharmaceuticals

Several large investors have recently modified their holdings of TFFP. Gagnon Securities LLC lifted its holdings in shares of TFF Pharmaceuticals by 12.4% during the 2nd quarter. Gagnon Securities LLC now owns 284,361 shares of the company’s stock valued at $1,607,000 after purchasing an additional 31,342 shares in the last quarter. Vanguard Group Inc. raised its holdings in TFF Pharmaceuticals by 6.5% during the 1st quarter. Vanguard Group Inc. now owns 864,983 shares of the company’s stock worth $5,458,000 after buying an additional 52,813 shares during the period. UBS Group AG raised its holdings in TFF Pharmaceuticals by 12.3% during the 2nd quarter. UBS Group AG now owns 92,177 shares of the company’s stock worth $521,000 after buying an additional 10,123 shares during the period. State Street Corp increased its position in shares of TFF Pharmaceuticals by 8.1% during the first quarter. State Street Corp now owns 69,929 shares of the company’s stock worth $441,000 after acquiring an additional 5,251 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of TFF Pharmaceuticals during the third quarter worth $84,000. 16.46% of the stock is currently owned by institutional investors.

About TFF Pharmaceuticals

(Get Rating)

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.

Read More

Insider Buying and Selling by Quarter for TFF Pharmaceuticals (NASDAQ:TFFP)

Receive News & Ratings for TFF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TFF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.